Actively Recruiting
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Led by Shanghai Hengrui Pharmaceutical Co., Ltd. · Updated on 2025-04-22
400
Participants Needed
1
Research Sites
192 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.
CONDITIONS
Official Title
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years
- At least one measurable lesion according to RECIST v1.1 criteria
- ECOG performance status of 0 or 1
- Expected survival of at least 12 weeks
- Good organ function
- Ability to provide informed consent and follow the treatment plan
- Use of effective contraception for males with partners of childbearing age and fertile females
You will not qualify if you...
- Untreated or uncontrolled active central nervous system metastases
- Spinal cord compression not treated by surgery or radiotherapy
- Uncontrolled tumor-related pain
- Received antitumor therapy within 4 weeks before study start
- Severe cardiovascular or cerebrovascular disease
- History of immunodeficiency, including positive HIV test
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanxi Cancer hospital
Taiyuan, Shanxi, China, 030001
Actively Recruiting
Research Team
Y
Yang Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here